11-Hydroxynoracronycine is a **natural alkaloid** isolated from the **Chinese medicinal plant** *Acronychia pedunculata*. It's a **potential therapeutic agent** with a range of promising biological activities, making it a subject of significant research interest.
**Here's why it's important for research:**
* **Anti-cancer activity:** 11-Hydroxynoracronycine exhibits potent cytotoxicity against a range of human cancer cell lines, including leukemia, breast, and colon cancer. This potent activity is linked to its ability to induce apoptosis (programmed cell death) in cancer cells.
* **Anti-inflammatory activity:** Studies have shown that 11-Hydroxynoracronycine possesses anti-inflammatory properties, potentially useful for treating inflammatory conditions like arthritis and asthma.
* **Antioxidant activity:** This compound exhibits antioxidant activity, scavenging free radicals and protecting cells from oxidative damage, which can contribute to various diseases like cancer, heart disease, and Alzheimer's disease.
* **Anti-bacterial activity:** Some studies have shown that 11-Hydroxynoracronycine has antibacterial activity, potentially useful for developing new antibiotics.
**Current research focuses on:**
* **Understanding its mechanism of action:** Researchers are investigating the specific cellular pathways and targets involved in 11-Hydroxynoracronycine's biological activities.
* **Developing new drug candidates:** Studies are underway to optimize the structure of 11-Hydroxynoracronycine and develop more effective and safe drug candidates for treating various diseases.
* **Clinical trials:** Pre-clinical studies have shown promising results, and clinical trials are necessary to evaluate the safety and efficacy of 11-Hydroxynoracronycine in humans.
**Overall, 11-Hydroxynoracronycine holds significant potential as a therapeutic agent due to its diverse biological activities. Ongoing research aims to unlock its full potential for treating various diseases and improving human health.**
11-hydroxynoracronycine: analog of acronycine from wood of Atalantia ceylanica; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Atalantia | genus | [no description available] | Rutaceae | A plant family in the order Sapindales that grows in warmer regions and has conspicuous flowers.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 5378702 |
| CHEMBL ID | 447169 |
| CHEBI ID | 69044 |
| MeSH ID | M0050585 |
| Synonym |
|---|
| bdbm50336483 |
| 7h-pyrano[2,3-c]acridin-7-one, 3,12-dihydro-6,11-dihydroxy-3,3,12-trimethyl- |
| 6,11-dihydroxy-3,3,12-trimethyl-pyrano[2,3-c]acridin-7-one |
| nsc162687 |
| 11-hydroxy-o-demethylacronine |
| 11-hydroxynoracronycine |
| alkaloid a from atalantia ceylanica |
| 7h-pyrano[2, 3,12-dihydro-6,11-dihydroxy-3,3,12-trimethyl- |
| 27067-70-5 |
| alkaloid a, from atalantia ceylanica |
| nsc-162687 |
| 5-hydroxynoracronycine |
| chebi:69044 , |
| CHEMBL447169 , |
| 3,12-dihydro-6,11-dihydroxy-3,312-trimethyl-7h-pyrano(2,3-c)acridin-7-one |
| unii-54e45u4q3n |
| 54e45u4q3n , |
| 7h-pyrano(2,3-c)acridin-7-one, 3,12-dihydro-6,11-dihydroxy-3,3,12-trimethyl- |
| nsc 162687 |
| JZQDCDLYNFZBIG-UHFFFAOYSA-N |
| 6,11-dihydroxy-3,3,12-trimethyl-3,12-dihydro-7h-pyrano[2,3-c]acridin-7-one # |
| DTXSID50181535 |
| 3,12-dihydro-6,11-dihydroxy-3,3,12-trimethyl-7h-pyrano(2,3-c)acridin-7-one |
| 5-hydroxynoracronycin |
| Q27137385 |
| Role | Description |
|---|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| acridines | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Cathepsin L2 | Homo sapiens (human) | IC50 (µMol) | 48.0000 | 0.0750 | 2.2141 | 10.0000 | AID568360 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| apoptotic process | Cathepsin L2 | Homo sapiens (human) |
| antigen processing and presentation of exogenous peptide antigen via MHC class II | Cathepsin L2 | Homo sapiens (human) |
| extracellular matrix disassembly | Cathepsin L2 | Homo sapiens (human) |
| immune response | Cathepsin L2 | Homo sapiens (human) |
| positive regulation of apoptotic signaling pathway | Cathepsin L2 | Homo sapiens (human) |
| positive regulation of peptidase activity | Cathepsin L2 | Homo sapiens (human) |
| proteolysis involved in protein catabolic process | Cathepsin L2 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| cysteine-type endopeptidase activity | Cathepsin L2 | Homo sapiens (human) |
| serine-type endopeptidase activity | Cathepsin L2 | Homo sapiens (human) |
| protein binding | Cathepsin L2 | Homo sapiens (human) |
| cysteine-type peptidase activity | Cathepsin L2 | Homo sapiens (human) |
| cysteine-type endopeptidase activator activity involved in apoptotic process | Cathepsin L2 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular region | Cathepsin L2 | Homo sapiens (human) |
| lysosomal lumen | Cathepsin L2 | Homo sapiens (human) |
| extracellular space | Cathepsin L2 | Homo sapiens (human) |
| lysosome | Cathepsin L2 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID357918 | Cytotoxicity against human HeLa cells after 72 hrs by [3H]hypoxanthine incorporation assay | 2001 | Journal of natural products, Sep, Volume: 64, Issue:9 | Bioactive acridone alkaloids from Swinglea glutinosa. |
| AID357913 | Antiplasmodial activity after 24 hrs against chloroquine-sensitive Plasmodium falciparum Nigerian by [3H]hypoxanthine uptake | 2001 | Journal of natural products, Sep, Volume: 64, Issue:9 | Bioactive acridone alkaloids from Swinglea glutinosa. |
| AID379437 | Antiproliferative activity against human CCRF-HSB-2 cells after 3 days by alamar blue assay | 1999 | Journal of natural products, Apr, Volume: 62, Issue:4 | The antiproliferative effect of acridone alkaloids on several cancer cell lines. |
| AID636825 | Antitrypanosomal activity against Trypanosoma brucei brucei | 2011 | Journal of natural products, Oct-28, Volume: 74, Issue:10 | Structure and in vitro antiparasitic activity of constituents of Citropsis articulata root bark. |
| AID636827 | Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for chloroquine-resistant Plasmodium falciparum FcB1/Colombia | 2011 | Journal of natural products, Oct-28, Volume: 74, Issue:10 | Structure and in vitro antiparasitic activity of constituents of Citropsis articulata root bark. |
| AID636823 | Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum FcB1/Colombia infected in human A+ve erythrocytes assessed as inhibition of [G-3H]hypoxanthine uptake preincubated for 24 hrs prior to [G-3H]hypoxanthine addition measured after 1 | 2011 | Journal of natural products, Oct-28, Volume: 74, Issue:10 | Structure and in vitro antiparasitic activity of constituents of Citropsis articulata root bark. |
| AID357917 | Cytotoxicity against human HeLa cells after 24 hrs by [3H]hypoxanthine incorporation assay | 2001 | Journal of natural products, Sep, Volume: 64, Issue:9 | Bioactive acridone alkaloids from Swinglea glutinosa. |
| AID357915 | Antiplasmodial activity after 24 hrs against chloroquine-resistant Plasmodium falciparum FcM29 by [3H]hypoxanthine uptake | 2001 | Journal of natural products, Sep, Volume: 64, Issue:9 | Bioactive acridone alkaloids from Swinglea glutinosa. |
| AID357916 | Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum FcM29 after 72 hrs by [3H]hypoxanthine uptake | 2001 | Journal of natural products, Sep, Volume: 64, Issue:9 | Bioactive acridone alkaloids from Swinglea glutinosa. |
| AID357920 | Selectivity index, ratio of ED50 for human HeLa cells to IC50 for Plasmodium falciparum Nigerian after 72 hrs by [3H]hypoxanthine incorporation assay | 2001 | Journal of natural products, Sep, Volume: 64, Issue:9 | Bioactive acridone alkaloids from Swinglea glutinosa. |
| AID357919 | Selectivity index, ratio of ED50 for human HeLa cells to IC50 for Plasmodium falciparum Nigerian after 24 hrs by [3H]hypoxanthine incorporation assay | 2001 | Journal of natural products, Sep, Volume: 64, Issue:9 | Bioactive acridone alkaloids from Swinglea glutinosa. |
| AID568360 | Inhibition of human recombinant cathepsin V expressed in Pichia pastoris | 2011 | Bioorganic & medicinal chemistry, Feb-15, Volume: 19, Issue:4 | Acridone alkaloids as potent inhibitors of cathepsin V. |
| AID636824 | Antileishmanial activity against Leishmania donovani MHOM/ET/L82/LV9 promastigotes after 3 days by MTT assay | 2011 | Journal of natural products, Oct-28, Volume: 74, Issue:10 | Structure and in vitro antiparasitic activity of constituents of Citropsis articulata root bark. |
| AID636826 | Cytotoxicity against african green monkey Vero cells | 2011 | Journal of natural products, Oct-28, Volume: 74, Issue:10 | Structure and in vitro antiparasitic activity of constituents of Citropsis articulata root bark. |
| AID357914 | Antiplasmodial activity after 72 hrs against chloroquine-sensitive Plasmodium falciparum Nigerian by [3H]hypoxanthine uptake | 2001 | Journal of natural products, Sep, Volume: 64, Issue:9 | Bioactive acridone alkaloids from Swinglea glutinosa. |
| AID379438 | Antiproliferative activity against human TGBC11TKB cells after 3 days by alamar blue assay | 1999 | Journal of natural products, Apr, Volume: 62, Issue:4 | The antiproliferative effect of acridone alkaloids on several cancer cell lines. |
| AID379435 | Antiproliferative activity against human A549 cells after 3 days by alamar blue assay | 1999 | Journal of natural products, Apr, Volume: 62, Issue:4 | The antiproliferative effect of acridone alkaloids on several cancer cell lines. |
| AID379436 | Antiproliferative activity against mouse B16 cells after 3 days by alamar blue assay | 1999 | Journal of natural products, Apr, Volume: 62, Issue:4 | The antiproliferative effect of acridone alkaloids on several cancer cell lines. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.94) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||